Are animal studies of antipsychotics appropriately dosed?: Lessons from the bedside to the bench

Canadian Journal of Psychiatry

Volumn 45, Issue 3, 2000, Pages 241-246

  Kapur, Shitij ^a,b   Wadenberg, Marie Louise ^a   Remington, Gary ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Animal models; Antipsychotics; Atypical; Dopamine; Haloperidol

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; CATALEPSY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW;

EID: 0034121999     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370004500302     Document Type: Review

References (28)

1. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic dopamine receptors. Nature 1976;261:717-9.
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 1976; 192:481-3.
3. Seeman P, Tallenco T Antipsychotic drags which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Molecular Psychiatry 1998;3:123-34.
4. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
5. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, and others. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
6. Kapur S, Zipursky R, Jones C, Remington G, Houle S. The relationship between dopamine D2 occupancy, clinical response and side effects - a double blind PET study in first episode Schizophrenia. Am J Psychiatry 2000. Forthcoming.
7. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-45.
8. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med 1994;24:307-16.
9. Huang HF, Jann MW, Wei FC, Chang TP, Chen JS, Juang DJ, and others. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. J Clin Pharmacol 1996;36:963-9.
10. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacol 1992;106:433-8.
11. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, and others. High levels of dopamine D2 receptor occupancy with low dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
12. Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, and others. The relationship between D-2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacol 1997;131:148-52.
13. Cheng YF, Paalzow I.K. Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 1992;13:69-76.
14. Seeman P, Kapur S. Clozapine occupies high levels of dopamine D2 receptors. Life Sci 1997;60:PL207-PL216.
15. Wadenberg M-L, Kapur S, Soliman A, Jones C, Wilson AA, Vaccarino F. Quantitative relationship between dopamine D2 receptor occupancy and catalepsy in rats. Society for Neuroscience Meeting, 1999:60.
16. Wadenberg M-L, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test also for the detection of potentially atypical antipsychotics? Neuroscience and Biobehavioral Reviews 1999;23:851-62.
17. Sanberg PR. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 1980;284:472-3.
18. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacol (Berl) 1995;120:128-33.
19. Wadenberg ML, Ahlenius S. Effects of raclopride and haloperidol on spontaneous motor activity and on conditioned avoidance behavior in rats. A comparison of potency, efficacy and time-course of action. Arzneimittelforschung 1991;41:692-5.
20. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
21. Limbird L. Cell surface receptors: a short course on theory and methods. Boston: Kluwer Academic Publishers; 1986.
22. Dragunow M, Robertson GS, Faull RL, Robertson HA, Jansen K. D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neurosci 1990;37:287-94.
23. Robertson GS, Matsumura H, Fibiger HC, Induction patterns of Fos-like immuno-reactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058-66.
24. Pinna A, Wardas J, Cozzolino A, Morelli M. Involvement of adenosine A2A receptors in the induction of c-Fos expression by clozapine and haloperidol. Neuropsychopharmacol 1999;20:44-51.
25. Sun YJ, Suzuki M, Kurachi T, Murata M, Kurachi M. Expression of Fos protein in the limbic regions of the rat following haloperidol decanoate. Brain Res 1998,791:125-36.
26. Bunney BS, Walters JR, Roth RH, Aghajanian GK. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 1973;185:560-71.
27. Bunney BS, Grace AA. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 1978;23:1715-27.
28. Kapur S, Zipursky R, Jones C, Shammi C, Remington G, Seeman P. Antipsychotic effect with only transient D2 occupancy: a clinical PET study of quetiapine. Arch Gen Psychiatry. Forthcoming.